HEPARIN KINETICS IN THROMBOEMBOLISM/Hirsh
نویسنده
چکیده
of transfused human platelets. Blood 26: 732, 1965 7. Paulus JM: Platelet Kinetics. Amsterdam, North Holland Publishing Co, 1971, ch 5 8. Hill AG: Principles of Medical Statistics. London, The Lancet Limited, 1961, ch XII 9. Isacson S, Nilsson IM: Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis. Acta Chir Scand 138: 313, 1972 10. Bergstrom K, Lahnborg G: The effect of major surgery, low doses of heparin and thromboembolism on plasma antithrombin. Comparison of immediate thrombin inhibiting capacity and the antithrombin III content. Thromb Res 6: 223, 1975 11. Marciniak E, Farley CH, DeSimone PA: Familial thrombosis due to antithrombin III deficiency. Blood 43: 219, 1974 12. Mustard JF: Platelets in thromboembolic disease. Adv Cardiol 4: 131, 1970 13. Greenberg J, Packham MA, Cazenave J, Mustard JF: Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 32: 476, 1975 14. Mester L, Szabados L, Born GVR, Michal F: Changes in the aggregation of platelets enriched in sialic acid. Nature New Biol 236: 213, 1972 15. Bosman HB: Platelet adhesiveness and aggregation. II. Surface sialic acid, glycoprotein: N-acetylneuraminic acid transferace and neuraminidase of human blood platelets. Biochim Bioph Acta 279: 456, 1972 16. Vreeken J, Van Aken WG: Spontaneous aggregation of blood platelets as a cause of idiopathic thrombosis and recurrent painful toes and fingers. Lancet 2: 1394, 1971 17. Wu KK, Hoak JC: Spontaneous platelet aggregation in arterial insufficiency: Mechanisms and implications. Blood 44: 934, 1974 18. Weiss HJ, Aldort LM, Kochwa S: The effect of salicylates on the hemostatis properties of platelets in man. J Clin Invest 47: 2169, 1968 19. Harker LA, Slichter SJ: Arterial and venous thromboembolism: Kinetic characterization and evaluation of therapy. Thromb Diath Haemorrh 31: 188, 1974
منابع مشابه
Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina.
Low-molecular-weight heparins (LMWHs) are a new class of anticoagulants derived from unfractionated heparin (UFH). They have a number of advantages over UFH that have led to their increasing use for a number of thromboembolic indications. This article will review the limitations of UFH and the mechanisms by which LMWHs overcome these limitations and discuss the results of recent clinical trials...
متن کاملComparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
CONTEXT When unfractionated heparin is used to treat acute venous thromboembolism, it is usually administered by intravenous infusion with coagulation monitoring, which requires hospitalization. However, subcutaneous administration of fixed-dose, weight-adjusted, unfractionated heparin may be suitable for inpatient and outpatient treatment of venous thromboembolism. OBJECTIVE To determine if ...
متن کاملDuration of anticoagulant therapy for venous thromboembolism.
The Medical Journal of Australia ISSN: 0025729X 15 June 2009 190 12 659-660 ©The Medical Journal of Australia 2009 www.mja.com.au Editorials days with unfractionated heparin, low-molecular-wei fondaparinux, prevents thrombus progression and re of recurrent VTE and death during the acute ph treatment is continued beyond the acute phase, wa the risk of recurrent VTE but increases the risk of requ...
متن کاملHemorrhagic complications of anticoagulant treatment.
Bleeding is the major complication of anticoagulant therapy. The criteria for defining the severity of bleeding varied considerably between studies, accounting in part for the variation in the rates of bleeding reported. Since the last review, there have been several meta-analyses published on the rates of major bleeding in trials of anticoagulants for atrial fibrillation and ischemic heart dis...
متن کاملVena cava filters reduced long-term risk for pulmonary embolism in proximal deep venous thrombosis.
M e t h o d s Design: 2 × 2 factorial randomized controlled trial (Prévention du Risque d’Embolie Pulmonaire par Interruption Cave [PREPIC] study). Allocation: Concealed.* Blinding: Blinded (data collectors and the adjudication committee that reviewed all documented outcome events).* Follow-up period: 8 years. Setting: 44 hospitals in France. Patients: 400 patients ≥ 18 years of age (mean age 7...
متن کامل